New flu vaccine candidates show promise in early trial
NCT ID NCT04451954
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This Phase 1 study tested several versions of a quadrivalent recombinant influenza vaccine, some with an adjuvant, in 210 healthy adults aged 18-30 and 50+. The main goals were to check safety and measure antibody responses against flu strains. Researchers compared different H3 antigens and the effect of adding an adjuvant to see if it boosts immunity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Quadrivalent recombinant influenza vaccine with or without adjuvant
What this could lead to
If successful, this could lead to a more effective flu vaccine that provides broader protection against different flu strains.
What could go wrong
This is an early Phase 1 trial focused on safety and immune response, not on preventing flu. The vaccine may not work as well in real-world settings or against future flu strains.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number 8400001
Peoria, Illinois, 61614, United States
-
Investigational Site Number 8400002
Melbourne, Florida, 32934, United States
-
Investigational Site Number 8400003
San Diego, California, 92108, United States
-
Investigational Site Number 8400004
Orlando, Florida, 32806, United States
-
Investigational Site Number 8400005
Rockville, Maryland, 20850, United States